Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
This randomized trial compared chemoradiotherapy alone to chemoradiotherapy followed by consolidation therapy with the PDL-1 antibody durvalumab in patients with stage III NSCLC. The treatment group had significantly improved progression-free survival, response rate, and overall survival, with clinically meaningful differences between the groups. The findings suggest that such regimens may be the new standard of care in these patients.
This is practice changing for inoperable stage 3 lung cancer.